Wednesday, 26 August 2026European Markets

ABL Diagnostics Stock Over 26% Down In The Last 10 Sessions

Loading stream...

(vianews) - shares of abl diagnostics (cac 40: abld.pa) dropped by a staggering 26.52% in 10 sessions from €11.84 to €8.70 at 16:39 est on thursday, after five successive sessions in a row of losses. cac 40 is rising 0.92% to €6,948.73, following the last session's downward trend.

about abl diagnostics

abl diagnostics société anonyme does not have significant operations. the company was formerly known as etablissements fauvet girel and changed its name to abl diagnostics société anonyme in april 2022. the company is headquartered in paris, france. abl diagnostics société anonyme is a subsidiary of advanced biological laboratories (abl) s.a.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, abl diagnostics's stock is considered to be overbought (>=80).

volatility

abl diagnostics's last week, last month's, and last quarter's current intraday variation average was a negative 11.04%, a negative 11.06%, and a positive 14.72%.

abl diagnostics's highest amplitude of average volatility was 11.04% (last week), 11.06% (last month), and 14.72% (last quarter).

more news about abl diagnostics (abld.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com